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ABSTRACT 
Perphenazine is an atypical anti-psychotic drug. It indicated for the treatment of a agitated depression in low doses together with an anti-
depressant.  Perphenazine has sedation and anxiolytic properties and also useful for the treat psychosis like schizopheria and manic phases of 
bi-polar dis-orders. The simple and accurate and precise absorption ratio method has been developed for the simultaneous estimation of 
Perphenazine in the pure drug form. The absorption maxima was found to be 310nm in the Method A (0.1N HCL Buffer) and shows linearity 
over the concentration range of 0.002-0.02 µg/mL with regression equation y=0.5372x-0.0099(r2 = 0.9990). In Method B (Sodium acetate 
buffer, pH 4.5) the drug obeys Beer Lambert’s law (λmax 310nm) in the concentration range of 0.002-0.02 µg/mL with regression equation 
y=0.4257x - 0.0084(r2= 0.9992). In Method C (Phosphate buffer, pH 6.8) the drug obeys Beer Lambert’s law (λmax 310nm) in the concentration 
range of 0.002-0.02 µg/mL with regression equation y=0.482x - 0.0074(r2= 0.9991). In Method D (phosphate buffer, pH 7.2) the drug obeys 
Beer Lambert’s law (λmax 310nm) in the concentration range of 0.002-0.02 µg/mL with regression equation y=0.3686x - 0.0055(r2= 0.9992). In 
Method E (0.1N NaoH Buffer) and shows linearity over the concentration range of 0.002-0.02 µg/mL with regression equation y=0.4864x-
0.0081(r2 = 0.999). In Method F (Methanol) the drug obeys Beer Lambert’s law (λmax 300nm) in the concentration range of 0.002-0.02 µg/mL 
with regression equation y=0.6323x - 0.003(r2= 0.999). In Method G (Ethanol ) the drug obeys Beer Lambert’s law (λmax 300nm) in the 
concentration range of 0.002-0.02 µg/mL with regression equation y=0.3686x - 0.0055(r2= 0.9991).   First derivative spectrophotometric 
methods (A1, B1, C1, D1, E1, F1 and G1) were developed in 0.1NHCl and Sodium acetate pH 4.5 and phosphate buffer, in pH 6.8 and phosphate 
buffer, pH 7.2, 0.1N NaoH Buffer, which Perphenazine obeys Beer Lambert’s law(λmax310nm) in the concentration range of 0.002-0.02 µg/mL 
and  0.002-0.02 µg/mL and    0.002-0.02 µg/mL  and 0.002-0.02 µg/mL and0.002-0.02 µg/mL  with regression equations y=0.0357x - 0.0006 
and y=0.0201x+0.0004 and y=0.0196x-0.0002 and y=0.0162x+0.0002  and y=0.0239x - 0.0002  and Perphenazine obeys Beer Lambert’s 
law(λmax300nm) for methanol and ethanol in the concentration range of 0.002-0.02 µg/mL and  0.002-0.02 µg/mL  with regression equations 
y=0.0423x-0.0003 and y=0.0371x+0.0003 respectively. The proposed spectrophotometric methods were validated as per the ICH guidelines 
and can be applied for the determination of Perphenazine in pharmaceutical formulations.  
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1. INTRODUCTION 
Perphenazine, chemically known as 2[4-(3-(2-
chlorophenothiazin-10-yl) propyl) piperazin-1-yl) ethanol] 
indicates for the treatment of an agitated depression 1 and 
also for the treat pyschosis- like schizophrenia and manic 
phases of bi-polar dis-order. Perphenazine is a 
phenothiazine derivative and a dopamine antagonist with 
anti-emetic and anti-psychotic dopamine 2(D2) receptors in 
the mesolimbic and medullary chemoreceptor trigger zone 
(CTZ) thereby preventing the excess of dopamine in the 
brain. This leads to reduction in psychotic symptoms, such 
as hallucinatins and delusions 2.  
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Figure 1: Structure of Perphenazine 
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Perphenazine appears to exert its anti-emetic activity by 
blocking the dopamine and histamine-1 receptors in CTZ 
thereby relieving nausea and vomiting in the brain. In 
addition, Perphenazine binds to alpha-adnergic receptors. 
Literature survey revealed that Perphenazine was 
determined by UV-Visible spectroscopy 3. In the present 
study, the authors have proposed seven simple validated 
spectrophotometric methods3 for the determination of 
Perphenazine in the pure drug form. 
MATERIALS AND METHODS 
2.1 Instrumentation 
A double beam UV-VIS spectrophotometer (UV-1800, 
Shimadzu, Japan) associated with a computer loaded with 
spectra manager programming UV Probe was utilized with a 
spectral bandwidth of 1nm and wavelength accuracy of ± 0.3 
nm with a pair of 10 mm way length matched quartz cells. 
For scanning, the wavelength range chosen was 400nm to 
200nm with medium scanning speed. All weights were taken 
on the electronic balance (Shimadzu).  
2.2 Chemicals and reagents  
HPLC grade Methanol (Merck), glacial acetic acid (Merck), 
sodium acetate trihydrate (Merck), Hydrochloric acid 
(Rankem), potassium Di-hydrogen phosphate (Merck), 
sodium hydroxide (Merck), Ethanol (Merck) was used. 
Perphenazine, obtained as a gift sample from, CHEMO 
(India), was used. 
2.3 Preparation of 0.1N Hcl  
8.5mL of 35% Conc. Hydrochloric acid was added to the 
1000mL volumetric flask containing 900mL de-ionized 
water and mixed well. The volume was then made up to 
1000mL with water. 
2.4 Preparation of Sodium Acetate Buffer (pH 4.5) 
Sodium acetate trihydrate (2.99 gm)were weighed 
accurately in a 1000ml volumetric flask containing 1000ml 
deionized water and mixed well, then 1.7mL glacial acetic 
acid was added to it and the pH adjusted to 4.50 with glacial 
acetic acid. 
2.5 Preparation of phosphate buffer pH 6.8: 
6.8grams of potassium Di-hydrogen phosphate and 0.9grams 
of sodium hydroxide were weighed accurately and was 
added in a 1000ml volumetric flask containing 900ml 
deionized water and mixed well. The volume was made up to 
1000ml with water. 
2.6 Preparation of phosphate buffer pH 7.2: 
6.8grams of potassium Di-hydrogen phosphate and 1.4grams 
of sodium hydroxide were weighed accurately and was 
added in a 1000ml volumetric flask containing 900ml 
deionized water and mixed well. The volume was made up to 
1000ml with water. 
2.7 Preparation of 0.1N NaoH Buffer: 
 4grams of sodium hydroxide was weighed accurately and 
was added in a 1000ml volumetric flask containing 900ml 
deionized water and mixed well. The volume was made up to 
1000ml with water. 
2.8 Preparation of stock solution: 
The standard solution of Perphenazine was prepared by 
dissolving accurately about 25 mg of the Perphenazine with 
methanol in a 25 ml volumetric flask.  
The stock solution was further diluted with 0.1N HCl and pH 
4.5 sodium acetate buffer and phosphate buffer pH 6.8 and 
phosphate buffer 7.2 and 0.1N NaoH buffer and Methanol 
buffer and Ethanol buffer  for method A (0.002-0.02µg/mL) 
and method B (0.002-0.02µg/mL) method C (0.002-
0.02µg/mL) and method D (0.002-0.02µg/mL) and method 
E (0.002-0.02µg/mL) method F (0.002-0.02µg/mL) and 
method G (0.002-0.02µg/mL) respectively as per the 
requirement. 
2.9 Procedure for preparation of Calibration curve: 
The drug solutions were scanned (200-400 nm) against the 
reagent blank (0.1N HCl for method A and sodium acetate 
buffer pH 4.5 for method B and phosphate buffer pH 6.8 for 
method C and phosphate buffer pH 7.2 for method D and 
0.1N NaoH buffer for method E and Methanol buffer for 
method F and Ethanol buffer for method G) the absorption 
spectra were recorded. The absorption maximum (λmax) was 
observed at 310 nm for methods A, B, C, D and E and 
absorption maximum (λmax) was observed at 300 nm for 
methods F and G . The absorption spectra so obtained were 
converted in to first derivative spectra by the inbuilt 
software of the instrument and the resulting spectrum 
shows both maxima and minima and therefore the 
magnitude of the amplitude was recorded against 
concentration for method A, B, C, D, E, F and G. Calibration 
curves were constructed by taking the concentration of the 
drug solutions on the x-axis and 
The corresponding absorbance values on the y-axis. 
2.10 Validation Procedure: 
The proposed method was optimised using methanol as 
stock solvent. Hcl(Method A) and various buffers (method B, 
C, D, E, F and G) as diluted solvents. The present method was 
validated for the various parameters as per ICH guidelines 
[3]. 
2.11 Precision and Accuracy 
The precision and accuracy studies were performed as per 
the ICH guidelines. The absorbance of six replicates (0.01 μg 
/mL) and the % RSD was calculated [3]. 
Accuracy was evaluated as per the ICH guidelines by the 
percent recovery studies by the addition of 50%, 100%, and 
150% of Perphenazine solution was taken and the % RSD 
was calculated. 
2.12 Limit of Detection and Limit of Quantification 
ICH guideline describes several approaches to determine the 
detection and quantification limits. These include visual 
evaluation, signal to- noise ratio and the use of standard 
deviation of the response and the slope of the calibration 
curve. The LOD and LOQ were based on the third approach 
and were calculated according to the 3.3σ/S and 10 σ/S 
criterions, respectively, where σ is the standard deviation of 
the S-intercepts of the regression lines and σ is the slope of 
the calibration curve. 
 3. RESULTS  
New spectrophotometric methods were developed for the 
determination of perphenazine in pharmaceutical 
preparations. Perphenazine has shown absorption maxima 
(λmax) at 310 nm in 0.1N Hcl (Method A) and Sodium acetate 
buffer pH 4.5 (Method B) and phosphate buffer pH 6.8 
(method C) and phosphate buffer pH 7.2 (method D)  and 
0.1N NaoH Buffer (Method E) and Perphenazine has shown 
absorption maxima (λmax) at 300 nm in Methanol buffer 
(Method F) and Ethanol buffer (Method G) the 
corresponding absorption spectra were shown in Figures.  
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Figure 2: Absorption spectrum of Perphenazine (1.0µg 
/mL) in 0.1N HcL Buffer 
 
Figure 3: Absorption spectrum of Perphenazine (1.0µg 
/mL) in Acetate Buffer pH4.5 
 
Figure 4: Absorption spectrum of Perphenazine (1.0µg 
/mL) in Phosphate Buffer pH6.8 
 
Figure 5: Absorption spectrum of Perphenazine (1.0µg 
/mL) in Phosphate BufferpH7.2 
 
Figure 6: Absorption spectrum of Perphenazine (1.2µg 
/mL) in 0.1N NaoH Buffer 
 
Figure 7: Absorption spectrum of Perphenazine (1.0µg 
/mL) in Methanol buffer 
 
Figure 8: Absorption spectrum of Perphenazine (1.0µg 
/mL) in Ethanol Buffer 
In method A1 for 0.1N HcL buffer , Perphenazine has shown 
zero crossing points at 202.10, 257.78, 307.78, 398.20,   with 
maxima at 288.62 nm and minima at 328.15 nm in Figure 9 
and therefore the amplitude has been taken against the 
concentration for the construction of the calibration curve. 
Similarly, in method B1 for Acetate buffer pH4.5, has shown 
zero crossing point at 206.38, 228.98, 248.17, 272.31, 
301.19, 373.35 and with maxima at 239.21 nm and minima 
at 328.43 nm in Figure 10 and therefore the amplitude has 
been taken against the concentration for the construction of 
the calibration curve and therefore the amplitude has been 
taken against the concentration for the construction of the 
calibration curve. In method C1 for phosphate buffer pH 6.8, 
Perphenazine has shown zero crossing points at 202.05, 
225.75, 248.50, 272.16, 310.48, 380.45,   with maxima at 
237.91 nm and minima at 333.62 nm in Figure 11 and 
therefore the amplitude has been taken against the 
concentration for the construction of the calibration curve. 
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Similarly, in method D1 for phosphate buffer pH7.2, has 
shown zero crossing point at 201.77, 204.40, 204.88, 224.17, 
248.26, 272.67, 310.02, 397.27 and with maxima at 237.20 
nm and minima at 327.61 nm in Figure 12 and therefore the 
amplitude has been taken against the concentration for the 
construction of the calibration curve and therefore the 
amplitude has been taken against the concentration for the 
construction of the calibration curve. In method E1 for 0.1N 
NaoH buffer , Perphenazine has shown zero crossing points 
at 210.78, 225.16, 247.14, 311.01, 397.89 and  with maxima 
at 288.21 nm and minima at 327.89 nm in Figure 13 and 
therefore the amplitude has been taken against the 
concentration for the construction of the calibration curve. 
Similarly, in method F1 for Methanol buffer has shown zero 
crossing point at 205.98, 227.24, 261.48, 276.94, 301.92, 
393.67 and with maxima at 248.60 nm and minima at 320.60 
nm in Figure 14 and therefore the amplitude has been taken 
against the concentration for the construction of the 
calibration curve and therefore the amplitude has been 
taken against the concentration for the construction of the 
calibration curve. Similarly, in method G1 for Ethanol buffer 
has shown zero crossing point at 204.49, 223.39, 262.43, 
276.67, 301.14, 395.02 and with maxima at 250.16 nm and 
minima at 320.78 nm in Figure 15 and therefore the 
amplitude has been taken against the concentration for the 
construction of the calibration curve and therefore the 
amplitude has been taken against the concentration for the 
construction of the calibration curve. 
 
 
Figure 9: Overlay first derivative spectra (D1) of 
Perphenazine in 0.1N HCl 
 
 
Figure 10: Overlay first derivative spectra (D1) of 
Perphenazine in acetate buffer pH 4.5 
 
Figure 11: Overlay first derivative spectra (D1) of 
Perphenazine in phosphate buffer pH 6.8 
 
Figure 12: Overlay first derivative spectra (D1) of 
Perphenazine in phosphate buffer pH 7.2 
 
Figure 13: Overlay first derivative spectra (D1) of 
Perphenazine in 0.1N NaoH 
 
Figure 14: Overlay first derivative spectra (D1) of 
Perphenazine in Methanol buffer 
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Figure 15: Overlay first derivative spectra (D1) of 
Perphenazine in Ethanol buffer 
Beer’s law was obeyed in the concentration range of 0.002-
0.02 µg / mL for method A and A1 and 0.002-0.02 µg/mL for 
Method B and B1 and 0.002-0.02 µg/mL for Method C and 
C1 and0.002-0.02 µg/mL for Method D and D1 and 0.002-
0.02 µg/mL for Method E and E1 and0.002-0.02 µg/mL for 
Method F and F1 and 0.002-0.02 µg/mL for Method G and G1 
.  The linear regression equations were found to be y = 
0.5372x-0.0099,  y = 0.4257x - 0.0084, y=0.482x-0.0074,  
y=0.3686x-0.0055, y = 0.6323x+0.003, y= 0.5955x+0.0128, 
y= 0.0357x-0.0006 , y = 0.0201x + 0.0004, y=0.0196x-
0.0002, and y=0.0162x-0.0002, y=0.239x+0.0002, 
y=0.0423x-0.0003, y=0.0371x+0.0003 for method A, B, C ,D, 
E, F, G and H  and also for A1, B1, C1, D1, E1, F1 and 
G1Vrespectively (Figure 10) with correlation coefficient 
0.999, 0.9992, 0.9991, 0.9992, 0.999, 0.999 and 0.9991 and 
also for 1st derivatives 0.9995, 0.9993, 0.9993, 0.9993, 
0.9996, 0.9994, and 0.9992 respectively (Table 1). 
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Figure 16: Calibration curves of Perphenazine in method A, B, C, D, E & F  
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Figure 16: Calibration curves of Perphenazine in method G and also for A1, B1, C1, D1, E1, F1 and G1 
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Table1: Optical characteristics of Perphenazine 
Parameters 
Method 
A B C D A1 B1 C1 D1 
Beer-
Lambert’s 
limits (µg 
/mL) 
 
0.002-0.02 
 
0.002-0.02 
 
0.002-0.02 
 
0.002-0.02 
 
 
0.002-0.02 
 
 
0.002-0.02 
 
 
0.002-0.02 
 
 
0.002-
0.02 
λmax/Amplitu
de range 
(nm) 
 
310 
 
310 
 
310 
 
310 
 
 
289.00- 
327.81 
 
 
288.81- 
329.81 
 
 
289.00- 
328.61 
 
 
288.98- 
327.62 
Regression 
equation 
 
0.5372x+0
.0099 
 
0.4257x-
0.0084 
 
0.482x- 
0.0074 
 
0.3686x-
0.0055 
 
0.0357X- 
0.0006 
 
0.0201X+ 
0.0004 
 
0.0196X-
0.0002 
 
0.0162X
+ 
0.0002 
Slope 0.5372 0.4257 0.482 0.3686 0.0357 0.0201 0.0196 0.0162 
Intercept 0.0099 0.0084 0.0074 0.0055 0.0006 0.0004 0.0002 0.0002 
Correlation 
coefficient 
 
0.999 
 
0.9992 
 
0.9991 
 
0.9992 
 
 
0.9995 
 
 
0.9993 
 
0.9993 
 
0.9993 
Sandells 
Sensitivity 
1.56*10-
5µgcm-2 
2.33*10-
5µgcm-2 
2.02*10-
5µgcm-2 
2.39*10-
5µgcm-2 
 
2.65*10-
4µgcm-2 
 
5.45*10-
4µgcm-2 
5.33*10-
4µgcm-2 
6.13*10-
4µgcm-2 
 
Table 2: Optical characteristics of Perphenazine 
Parameters 
METHOD 
E F G E1 F1 G1 
Beer-Lambert’s limits (µg /mL) 0.002-0.02 0.002-0.02 0.002-0.02 0.002-0.02 0.002-0.02 0.002-0.02 
λmax/Amplitude range (nm) 
310 300 300 335.16-
341.15 
250.03- 
322.19 
250.18-
320..80 
Regression equation 
0.4864x+ 
0.0081 
0.6323x- 
0.003 
0.5955x+ 
0.0128 
0.0239x+ 
0.0002 
0.0423x- 
0.0003 
0.0371x+ 
0.0003 
Slope 0.4864 0.6323 0.5955 0.0239 0.0423 0.0371 
Intercept 0.0081 0.003 0.0128 0.0002 0.0003 0.0003 
Correlation coefficient 0.999 0.999 0.9991 0.9996 0.9994 0.9992 
Sandells Sensitivity 
2.68*10-
5µgcm-2 
1.94*10-
5µgcm-2 
1.64*10-
5µgcm-2 
2.58*10-
4µgcm-2 
2.57*10-
4µgcm-2 
2.64*10-
4µgcm-2 
 
 
The % RSD values in precision studies were found to be 0.12, 
0.28, 0.34, 0.45, 0.11, 0.28 and 0.35  for method  A, B, C, D, E, 
F and G respectively (RSD <2%)  and 0.24, 0.57, 0.69, 0.91, 
0.11, 0.28 and 0.35 for method  A1, B1, C1, D1, E1, F1 and G1 
respectively (RSD <2%)   indicating that the method is more 
precise. The % Recovery values (Tables 3 to 6)  were found  
to be 99.20%, 99.33%, 99.44%, 99.54%, 99.30 %, 99.44% 
and 99.54% with RSD 0.13, 0.39, 0.45, 0.56, 0.14, 0.49 and 
0.55 for method A, B, C, D, E, F and G respectively (RSD <2%) 
and the % Recovery values (Tables 3 to 6)  were found  to be 
99.42%, 99.22%, 99.57%, 99.60%, 99.66 %, 99.22% and 
99.64% with RSD 0.35, 0.68, 0.71, 0.93, 0.35, 0.48 and 0.69 
for method A1, B1, C1, D1, E1, F1 and G1 respectively (RSD 
<2%)   indicating that the proposed methods can be applied 
for the determination of pharmaceutical formulations and 
the method is more accurate.  
LOQ is defined as the lowest amount of analyte which can be 
detected. LOD was defined as the lowest amount of analyte 
which can be quantitatively determined. LOD and LOQ of the 
drug were calculated as per ICH guidelines. The Limit of 
Detection and Limit of Quantification was found to be 
0.33µg/ml and 0.0165µg/ml (Method A and A1) and 
0.165µg/mL and 0.00825µg/mL (Method B and B1) and 
0.66µg/ml and 0.0274µg/ml (Method C and C1) and 
0.495µg/ml and 0.033µg/ml (Method D and D1) and 
0.99µg/ml and 0.01625µg/ml (Method E and E1) and 
0.33µg/mL and 0.00825µg/mL (Method F and F1) and 
0.66µg/Ml and 0.00825 µg/Ml (Method G and G1) 
respectively.
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Table 3: Assay of API 
 
Level 
*Amount obtained (mg) 
Method 
A B C D      A1 B1 C1 D1 
50 0.4949 0.4954 0.4965 0.4974 0.4967 0.4964 0.4976 0.4953 
100 0.9959 0.9920 0.9971 0.9982 0.9942 0.9950 0.9963 0.9974 
150 0.9975 0.9940 0.9989 0.9996 0.9961 0.9989 0.9971 0.9985 
*Each value is average of three determinations 
 
Table 4: Assay of API 
 
Level 
*Amount obtained (mg) 
Method 
E F G E1 F1 G1 
50 0.4939 0.4944 0.4958 0.4966 0.4954 0.4964 
100 0.9959 0.9920 0.9970 0.9979 0.9961 0.9979 
150 0.9989 0.9940 0.9980 0.9995 0.9981 0.9985 
*Each value is average of three determinations 
 
Table 5: Assay of API 
 
Level 
% Recovery* 
Method 
A B C D A1 B1 C1 D1 
50   99.20 99.33 99.44 99.54 99.42 99.22 99.57 99.60 
100 99.51 99.22 99.61 99.74 99.41 99.50 99.71 99.81 
150 99.71 99.30 99.72 99.81 99.69 99.60 99.89 99.90 
 
Table 6: Assay of API 
 
Level 
% Recovery* 
Method 
E F G E1 F1 G1 
50 99.30 99.44 99.54 99.66 99.22 99.64 
`100 99.59 99.33 99.71 99.89 99.51 0.9967 
150 99.89 99.40 99.60 99.95 99.61 99.85 
*Each value is average of three determinations 
 
4. DISCUSSION 
The objective of the analytical procedure is to govern the 
validation characteristics which need to be evaluated. 
Typical validation characteristics which should be 
considered are listed below: Linearity, Accuracy, Precision, 
LOD, and LOQ. The calibration plot for linear regression data 
was indicative of a good linear relationship between 
concentration and peak area concentration over a wide 
range. The results have shown best recoveries (%) of the 
spiked drug at each added concentration, indicating that the 
method was accurate. The precision of Perphenazine was 
evaluated and the percentage relative standard deviation 
(%RSD) was found to be which proves that the method was 
precise. And the Limit of Detection and Limit of 
Quantification was found to be 0.33µg/ml and 0.0165µg/ml 
(Method A and A1 ) and 0.165µg/mL and 0.00825µg/mL 
(Method B and B1) and 0.66µg/ml and 0.0274µg/ml 
(Method C and C1) and 0.495µg/ml and 0.033µg/ml 
(Method D and D1) and 0.01625µg/ml (Method E and E1) 
and 0.33µg/mL and 0.00825µg/mL (Method F and F1) and 
0.66µg/Ml and 0.00825 µg/Ml (Method G and G1) 
respectively. Hence the proposed method was sensitive. 
 
CONCLUSION 
The present methods can be employed for the determination 
of Perphenazine in API. 
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